Tumor cells transfer between the patient and laboratory animal as a basic methodological approach to the study of cancerogenesis and identification of biomarkers
Authors:
Dušan Klos 1; M. Stašek 1; M. Loveček 1; P. Skalický 1; R. Vrba 1; R. Aujeský 1; R. Havlík 1; Č. Neoral 1; L. Varanashi 2; M. Hajdúch 2; J. Vrbková 2; P. Džubák 2
Authors‘ workplace:
I. chirurgická klinika FN a LF Univerzity Palackého v Olomouci
přednosta: prof. MUDr. Č. Neoral, CSc.
1; Ústav molekulární a translační medicíny LF Univerzity Palackého v Olomouci
ředitel: doc. MUDr. M. Hajdúch, Ph. D.
2
Published in:
Rozhl. Chir., 2016, roč. 95, č. 12, s. 432-438.
Category:
Original articles
Overview
Introduction:
The investigation of prognostic and predictive factors for early diagnosis of tumors, their surveillance and monitoring of the impact of therapeutic modalities using hybrid laboratory models in vitro/in vivo is an experimental approach with a significant potential. It is preconditioned by the preparation of in vivo tumor models, which may face a number of potential technical difficulties. The assessment of technical success of grafting and xenotransplantation based on the type of the tumor or cell line is important for the preparation of these models and their further use for proteomic and genomic analyses.
Methods:
Surgically harvested gastrointestinal tract tumor tissue was processed or stable cancer cell lines were cultivated; the viability was assessed, and subsequently the cells were inoculated subcutaneously to SCID mice with an individual duration of tumor growth, followed by its extraction.
Results:
We analysed 140 specimens of tumor tissue including 17 specimens of esophageal cancer (viability 13/successful inoculations 0), 13 tumors of the cardia (11/0), 39 gastric tumors (24/4), 47 pancreatic tumors (34/1) and 24 specimens of colorectal cancer (22/9). 3 specimens were excluded due to histological absence of the tumor (complete remission after neoadjuvant therapy in 2 cases of esophageal carcinoma, 1 case of chronic pancreatitis). We observed successful inoculation in 17 of 28 tumor cell lines.
Conclusion:
The probability of successful grafting to the mice model in tumors of the esophagus, stomach and pancreas is significantly lower in comparison with colorectal carcinoma and cell lines generated tumors. The success rate is enhanced upon preservation of viability of the harvested tumor tissue, which depends on the sequence of clinical and laboratory algorithms with a high level of cooperation.
Key words:
proteomic analysis – xenotransplantation – prognostic and predictive factors – gastrointestinal tract tumors
Sources
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646−74.
2. Tarazona N, Gambardella V, Huerta M, et al. Personalised treatment in gastric cancer: myth or reality? Curr Oncol Rep 2016;18:41.
3. Das V, Bruzzese F, Konečný P, et al. Pathophysiologically relevant in vitro tumor models for drug screening. Drug Discovery Today 2015;20:848−55.
4. Cho SY, Kang W, Han JY, et al. An Integrative approach to precision cancer medicine using patient-derived xenografts. Mol Cells 2016;39:77−86.
5. Chijiwa T, Kawai K, Noguchi A, et al. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. International Journal of Oncology 2015;47:61–70.
6. Van den Brink GR, Offerhaus GJ. The morphogenetic code and colon cancer development. Cancer Cell 2007;11:109–17.
7. Beer LA, Wang H, Tang H-Y, et al. Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera. PLoS ONE 2013;8:e60129.
8. Grote T, Logsdon CD. Progress on molecular markers of pancreatic cancer. Curr Opin Gastroenterol 2007;23:508−14.
9. Harsha HC, Kandasamy K, Ranganathan P, et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009; dostupný na: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000046.
10. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 2004;10:860−8.
11. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. Sep 26, 2008;321:1801–6.
12. Wilson, CJ, Zhan, H, Swint-Kruse, et al. The lactose repressor system: paradigms for regulation, allosteric behavior and protein folding. Cell Mol Life Sci 2007;64:3–16.
13. Vitkup D, Kharchenko P & Wagner A. Influence of metabolic network structure and function on enzyme evolution. Genome Biol 2006;7:R39.1–R39.9.
14. Julien S, Merino-Trigo A, Lacroix L, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res. 2012;18:5314−28.
15. Damhofer H, Ebbing EA, Steins A. Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract. J Transl Med 2015;13:115.
16. Jang R, Darling G, Wong RK. Multimodality approaches for the curative treatment of esophageal cancer. J Nati Compr Canc Netw 2015;13:229−38.
17. Zhu Y, Tian T, Li Z, et al. Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer. Sci Rep 2015;5:8542.
18. Humphries JM, Penno MA, Weiland F, et al. Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer. Biochim Biophys Acta 2014;1844:1051−8.
19. Van Cutsem E, Sagaert X, Topal B, et al. Gastric cancer. Lancet 2016 dostupné na: http://dx.doi.org/10.1016/S0140-6736(16)30354-3
20. Choi YY,Lee JE, Kim H, et al. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep 2016;6, dostupný na: http://www.nature.com/articles/srep22172
21. Delitto D, Pham K, Vlada AC, et al. Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Am J Pathol 2015;185:1297–1303.
22. Walters DM, Stokes JB, Adair SJ, et al. Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. PLoS One 2013;8: dostuný na: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0077065
23. Li J, Kil C, Considine K, et al. Intrinsic indicators for specimen degradation. Lab Invest 2013;93:242−53.
24. Ahmed FE. Sample preparation and fractionation for proteome analysis and cancer biomarker discovery by mass spectrometry. J Sep Sci 2009;32:771−98.
25. Mollo MR, Antonini D, Cirillo L, et al. Research techniques made simple: skin carcinogenesis models: xenotransplantation techniques. J Invest Dermatol 2016;136:e13−7.
26. Lee HJ, Lee EY, Kwon MS, et al. Biomarker discovery from the plasma proteome using multidimensional fractionation proteomics. Curr Opin Chem Biol 2006;10:42−9.
27. Dangles-Marie V, Pocard M, Richon S, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res 2007;67:398−407.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2016 Issue 12
Most read in this issue
- Rare case of a giant parathyroid adenoma
- 10 years of sleeve gastrectomy in the Czech Republic in terms of the surgical procedure
- Purtscher-like retinopathy as a complication of acute pancreatitis
- Proximal gastrectomy for adenocarcinoma of the gastroesophageal junction in a selected set of patients − immediate and long-term results